FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789778893> ?p ?o ?g. }

• W2789778893 endingPage "69" @default.
• W2789778893 startingPage "53" @default.
• W2789778893 abstract "Inhibition of the mechanistic target of rapamycin (mTOR) pathway by rapamycin (RAPA), an FDA-approved immunosuppressive drug used as a clinical therapy to prevent solid organ allograft rejection, enhances longevity in mice. Importantly, RAPA was efficacious even when initiated in relatively old animals, suggesting that mTOR inhibition could potentially slow the progression of aging-associated pathologies in older humans (Harrison et al., 2009; Miller et al., 2011). However, the safety and tolerability of RAPA in older human subjects have not yet been demonstrated. Towards this end, we undertook a placebo-controlled pilot study in 25 generally healthy older adults (aged 70–95 years); subjects were randomized to receive either 1 mg RAPA or placebo daily. Although three subjects withdrew, 11 RAPA and 14 controls completed at least 8 weeks of treatment and were included in the analysis. We monitored for changes that would indicate detrimental effects of RAPA treatment on metabolism, including both standard clinical laboratory assays (CBC, CMP, HbA1c) and oral glucose tolerance tests (OGTTs). We also monitored parameters typically associated with aging that could potentially be modified by RAPA; these included cognitive function which was assessed by three different tools: Executive Interview-25 (EXIT25); Saint Louis University Mental Status Exam (SLUMS); and Texas Assessment of Processing Speed (TAPS). In addition, physical performance was measured by handgrip strength and 40-foot timed walks. Lastly, changes in general parameters of healthy immune aging, including serum pro-inflammatory cytokine levels and blood cell subsets, were assessed. Five subjects reported potential adverse side effects; in the RAPA group, these were limited to facial rash (1 subject), stomatitis (1 subject) and gastrointestinal issues (2 subjects) whereas placebo treated subjects only reported stomatitis (1 subject). Although no other adverse events were reported, statistically significant decrements in several erythrocyte parameters including hemoglobin (HgB) and hematocrit (Hct) as well as in red blood cell count (RBC), red blood cell distribution width (RDW), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) were observed in the RAPA-treatment group. None of these changes manifested clinically significant effects during the short duration of this study. Similarly, no changes were noted in any other clinical laboratory, cognitive, physical performance, or self-perceived health status measure over the study period. Immune parameters were largely unchanged as well, possibly due to the advanced ages of the cohort (70–93 years; mean age 80.5). RAPA-associated increases in a myeloid cell subset and in TREGS were detected, but changes in most other PBMC cell subsets were not statistically significant. Importantly, the OGTTs revealed no RAPA-induced change in blood glucose concentration, insulin secretion, and insulin sensitivity. Thus, based on the results of our pilot study, it appears that short-term RAPA treatment can be used safely in older persons who are otherwise healthy; a trial with a larger sample size and longer treatment duration is warranted." @default.
• W2789778893 created "2018-03-29" @default.
• W2789778893 creator A5020649905 @default.
• W2789778893 creator A5024582072 @default.
• W2789778893 creator A5028433300 @default.
• W2789778893 creator A5031146498 @default.
• W2789778893 creator A5034471398 @default.
• W2789778893 creator A5054005032 @default.
• W2789778893 creator A5054069135 @default.
• W2789778893 creator A5055533149 @default.
• W2789778893 creator A5068979736 @default.
• W2789778893 creator A5074770263 @default.
• W2789778893 creator A5078177827 @default.
• W2789778893 creator A5080164174 @default.
• W2789778893 creator A5084129327 @default.
• W2789778893 creator A5091758197 @default.
• W2789778893 date "2018-05-01" @default.
• W2789778893 modified "2023-10-16" @default.
• W2789778893 title "A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects" @default.
• W2789778893 cites W1541192889 @default.
• W2789778893 cites W1572421661 @default.
• W2789778893 cites W1820532154 @default.
• W2789778893 cites W1890771959 @default.
• W2789778893 cites W1964983320 @default.
• W2789778893 cites W1966944043 @default.
• W2789778893 cites W1970763537 @default.
• W2789778893 cites W1973314755 @default.
• W2789778893 cites W1976726113 @default.
• W2789778893 cites W1977238326 @default.
• W2789778893 cites W1977587396 @default.
• W2789778893 cites W1978161786 @default.
• W2789778893 cites W1981217826 @default.
• W2789778893 cites W1983458614 @default.
• W2789778893 cites W1998052953 @default.
• W2789778893 cites W2000895251 @default.
• W2789778893 cites W2002732508 @default.
• W2789778893 cites W2007029142 @default.
• W2789778893 cites W2015191584 @default.
• W2789778893 cites W2018541629 @default.
• W2789778893 cites W2030587948 @default.
• W2789778893 cites W2034412853 @default.
• W2789778893 cites W2036730266 @default.
• W2789778893 cites W2038088215 @default.
• W2789778893 cites W2048376025 @default.
• W2789778893 cites W2059278059 @default.
• W2789778893 cites W2064380726 @default.
• W2789778893 cites W2064876347 @default.
• W2789778893 cites W2067503702 @default.
• W2789778893 cites W2074246253 @default.
• W2789778893 cites W2083647627 @default.
• W2789778893 cites W2089297859 @default.
• W2789778893 cites W2090187225 @default.
• W2789778893 cites W2090648684 @default.
• W2789778893 cites W2094602294 @default.
• W2789778893 cites W2101516052 @default.
• W2789778893 cites W2104285917 @default.
• W2789778893 cites W2110641805 @default.
• W2789778893 cites W2111577577 @default.
• W2789778893 cites W2114183739 @default.
• W2789778893 cites W2126028507 @default.
• W2789778893 cites W2133795831 @default.
• W2789778893 cites W2140146057 @default.
• W2789778893 cites W2142431174 @default.
• W2789778893 cites W2146823823 @default.
• W2789778893 cites W2149010238 @default.
• W2789778893 cites W2149076983 @default.
• W2789778893 cites W2155759076 @default.
• W2789778893 cites W2156003677 @default.
• W2789778893 cites W2156506572 @default.
• W2789778893 cites W2157444988 @default.
• W2789778893 cites W2160234571 @default.
• W2789778893 cites W2160837075 @default.
• W2789778893 cites W2169527297 @default.
• W2789778893 cites W2171106818 @default.
• W2789778893 cites W2173180239 @default.
• W2789778893 cites W2334913276 @default.
• W2789778893 cites W2395395500 @default.
• W2789778893 cites W2467269565 @default.
• W2789778893 cites W2521666083 @default.
• W2789778893 cites W2605299966 @default.
• W2789778893 cites W2607031541 @default.
• W2789778893 cites W2735735167 @default.
• W2789778893 cites W2772900830 @default.
• W2789778893 cites W4243966779 @default.
• W2789778893 cites W629012338 @default.
• W2789778893 doi "https://doi.org/10.1016/j.exger.2017.12.026" @default.
• W2789778893 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5869166" @default.
• W2789778893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29408453" @default.
• W2789778893 hasPublicationYear "2018" @default.
• W2789778893 type Work @default.
• W2789778893 sameAs 2789778893 @default.
• W2789778893 citedByCount "95" @default.
• W2789778893 countsByYear W27897788932018 @default.
• W2789778893 countsByYear W27897788932019 @default.
• W2789778893 countsByYear W27897788932020 @default.
• W2789778893 countsByYear W27897788932021 @default.
• W2789778893 countsByYear W27897788932022 @default.
• W2789778893 countsByYear W27897788932023 @default.

• next